PMID- 35538047
OWN - NLM
STAT- MEDLINE
DCOM- 20230105
LR  - 20230111
IS  - 2472-5625 (Electronic)
IS  - 2472-5625 (Linking)
VI  - 7
IP  - 1
DP  - 2023 Jan 3
TI  - Fluorodeoxyglucose-positron emission tomography/computed tomography-positive ear 
      lesions responsive to immunosuppressive therapy in a patient with otitis media 
      with antineutrophil cytoplasmic antibody-associated vasculitis.
PG  - 134-137
LID - 10.1093/mrcr/rxac044 [doi]
AB  - A 74-year-old woman presented with vertigo, left-beating nystagmus, and auditory 
      disturbance 4 months prior, in whom a former physician suspected Meniere's 
      disease. Her signs and symptoms mildly improved with a moderate dose of 
      glucocorticoids, which was eventually tapered. Fluorodeoxyglucose (FDG)-positron 
      emission tomography (PET)/computed tomography (CT) was performed 12 days prior to 
      routine examination. Remarkable FDG uptake was observed in the surrounding areas 
      of the bilateral Eustachian tubes and left middle ear, which was only partially 
      detected on magnetic resonance imaging. The patient also tested positive for 
      myeloperoxidase-antineutrophil cytoplasmic antibody (ANCA). She was admitted to 
      our hospital and diagnosed with otitis media with ANCA-associated vasculitis 
      (OMAAV) based on the classification criteria. Four months after immunosuppressive 
      therapy, the abnormal ear findings were not observed on follow-up FDG-PET/CT. The 
      clinical course of this case suggests that FDG-PET/CT can detect occult ear 
      involvement better than do other modalities in patients with OMAAV. In addition, 
      FDG-PET/CT-positive ear lesions responded to immunosuppressive therapy. 
      Therefore, FDG-PET/CT can help distinguish OMAAV from other ear diseases with 
      non-inflammatory aetiologies and detect occult treatment-responsive OMAAV lesions 
      in the clinical setting.
CI  - (c) Japan College of Rheumatology 2022. Published by Oxford University Press. All 
      rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
FAU - Murao, Yuki
AU  - Murao Y
AD  - Postgraduate Clinical Training Center, Hiroshima University Hospital, Hiroshima, 
      Japan.
FAU - Yoshida, Yusuke
AU  - Yoshida Y
AUID- ORCID: 0000-0002-0774-0509
AD  - Department of Clinical Immunology and Rheumatology, Hiroshima University 
      Hospital, Hiroshima, Japan.
FAU - Oka, Naoya
AU  - Oka N
AD  - Department of Clinical Immunology and Rheumatology, Hiroshima University 
      Hospital, Hiroshima, Japan.
FAU - Yorishima, Ai
AU  - Yorishima A
AD  - Department of Clinical Immunology and Rheumatology, Hiroshima University 
      Hospital, Hiroshima, Japan.
FAU - Masuda, Sho
AU  - Masuda S
AD  - Department of Clinical Immunology and Rheumatology, Hiroshima University 
      Hospital, Hiroshima, Japan.
FAU - Sugimoto, Tomohiro
AU  - Sugimoto T
AUID- ORCID: 0000-0002-0968-9081
AD  - Department of Clinical Immunology and Rheumatology, Hiroshima University 
      Hospital, Hiroshima, Japan.
FAU - Ono, Rina
AU  - Ono R
AD  - Department of Otolaryngology, Shobara Red Cross Hospital, Shobara, Japan.
FAU - Hirokawa, Yutaka
AU  - Hirokawa Y
AD  - Hiroshima Heiwa Clinic, Hiroshima, Japan.
FAU - Hirata, Shintaro
AU  - Hirata S
AUID- ORCID: 0000-0002-2474-9943
AD  - Department of Clinical Immunology and Rheumatology, Hiroshima University 
      Hospital, Hiroshima, Japan.
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Mod Rheumatol Case Rep
JT  - Modern rheumatology case reports
JID - 101761026
RN  - 0 (Antibodies, Antineutrophil Cytoplasmic)
RN  - 0Z5B2CJX4D (Fluorodeoxyglucose F18)
SB  - IM
MH  - Female
MH  - Humans
MH  - Aged
MH  - Antibodies, Antineutrophil Cytoplasmic
MH  - Positron Emission Tomography Computed Tomography
MH  - Fluorodeoxyglucose F18/therapeutic use
MH  - *Anti-Neutrophil Cytoplasmic Antibody-Associated 
      Vasculitis/complications/diagnosis/drug therapy
MH  - *Otitis Media/diagnosis/etiology/therapy
MH  - Immunosuppression Therapy/adverse effects
OTO - NOTNLM
OT  - ANCA-associated vasculitis
OT  - OMAAV
OT  - anti-neutrophil cytoplasmic antibody
OT  - fluorodeoxyglucose
OT  - positron emission tomography
EDAT- 2022/05/11 06:00
MHDA- 2023/01/06 06:00
CRDT- 2022/05/10 23:02
PHST- 2022/03/04 00:00 [received]
PHST- 2022/05/04 00:00 [revised]
PHST- 2022/05/09 00:00 [accepted]
PHST- 2022/05/11 06:00 [pubmed]
PHST- 2023/01/06 06:00 [medline]
PHST- 2022/05/10 23:02 [entrez]
AID - 6583472 [pii]
AID - 10.1093/mrcr/rxac044 [doi]
PST - ppublish
SO  - Mod Rheumatol Case Rep. 2023 Jan 3;7(1):134-137. doi: 10.1093/mrcr/rxac044.